[HTML] nih.gov

[HTML][HTML] DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

F Xu, L He, X Zhan, J Chen, H Xu, X Huang, Y Li… - Aging (albany …, 2020 - ncbi.nlm.nih.gov
The marked heterogeneity of lung adenocarcinoma (LUAD) makes its diagnosis and
treatment difficult. In addition, the aberrant DNA methylation profile contributes to tumor …
被引用次数：40 相关文章
[PDF] semanticscholar.org

[PDF][PDF] DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

F Xu, L He, X Zhan, J Chen, H Xu, X Huang, Y Li… - …, 2020 - pdfs.semanticscholar.org
The marked heterogeneity of lung adenocarcinoma (LUAD) makes its diagnosis and
treatment difficult. In addition, the aberrant DNA methylation profile contributes to tumor …

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

F Xu, L He, X Zhan, J Chen, H Xu, X Huang, Y Li… - …, 2020 - pubmed.ncbi.nlm.nih.gov
The marked heterogeneity of lung adenocarcinoma (LUAD) makes its diagnosis and
treatment difficult. In addition, the aberrant DNA methylation profile contributes to tumor …

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.

F Xu, L He, X Zhan, J Chen, H Xu, X Huang, Y Li… - Aging, 2020 - europepmc.org
The marked heterogeneity of lung adenocarcinoma (LUAD) makes its diagnosis and
treatment difficult. In addition, the aberrant DNA methylation profile contributes to tumor …

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.

F Xu, L He, X Zhan, J Chen, H Xu, X Huang, Y Li… - Aging, 2020 - europepmc.org
The marked heterogeneity of lung adenocarcinoma (LUAD) makes its diagnosis and
treatment difficult. In addition, the aberrant DNA methylation profile contributes to tumor …